Results 101 to 110 of about 103,602 (308)

Exploring downstream pathways of aberrantly activated kinases for targeted leukemia therapy [PDF]

, 2008
Genetic alterations resulting in uncontrolled protein tyrosine kinases (PTKs) activity are frequently found in leukemia and in human solid cancers. Although the development of small molecule kinase inhibitors has revolutionized therapy for PTKinduced ...
Gasser, Christelle
core   +1 more source

NUDT21 Drives T‐Cell Acute Lymphoblastic Leukemia Through Dual Regulation of Alternative Polyadenylation and Transcriptional Activation

Advanced Science, EarlyView.
In summary, our study defines a coordinated oncogenic model in which NUDT21 integrates alternative polyadenylation–dependent UBE2D3 stabilization and transcriptional activation to sustain MYC‐driven T‐ALL cell survival, thereby establishing NUDT21 as a central regulatory node and a promising therapeutic target.
Conglian Qiu, Jianwei Wang, Zhiheng Li, Qi Ji, Hui Zhang, Qinyi Zhang, Senlin Zhang, Juanjuan Yu, Yanfang Tao, Yijun Wu, Chunxia Shi, Zong Zai, Zimu Zhang, Yizhen Li, Zhenjiang Bai, Shaoyan Hu, Jian Pan, Yang Yang, Shuiyan Wu   +18 more
wiley   +1 more source

Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion

Advanced Science, EarlyView.
The applications of CAR T‐cell therapy in T‐cell malignancies face limitations such as fratricide, effector‐cell exhaustion, and antigen‐escape. Herein, we developed fratricide‐ and exhaustion‐resistant CAR‐T cells that targeted CCR4 and CD7 simultaneously, with optional EGFRt safety switch. Additionally, scRNA‐seq unveiled new molecular targets, which
Sile Li, Yuanxin Li, Asif Rashid, Hong Kee Tan, Shing Chan, Man Yan Hui, Wilson Yau Ki Chan, Kee See Lam, Yinping Liu, Wenwei Tu, Wing Leung   +10 more
wiley   +1 more source

The T-cell oncogene Tal2 is a Target of PU.1 and upregulated during osteoclastogenesis

, 2013
Transcription factors play a crucial role in regulating differentiation processes during human life and are important in disease. The basic helix-loop-helix transcription factors Tal1 and Lyl1 play a major role in the regulation of gene expression in the
Stefanie Herkt, Hussong, Helge, Helge Hussong, Christian Mücke, Jörn Lausen, Herkt, Stefanie, Nadine Courtial, Courtial, Nadine, Stephan Kolodziej, Kolodziej, Stephan, Lausen, Jörn, Mücke, Christian   +11 more
core   +1 more source

Peptide aptamers define distinct EB1- and EB3-binding motifs and interfere with microtubule dynamics [PDF]

, 2014
EB1 is a conserved protein that plays a central role in regulating microtubule dynamics and organisation. It binds directly to microtubule plus ends and recruits other plus end localising proteins.
Warbrick, Emma, Ohkura, Hiroyuki, Lesniewska, Karolina   +2 more
core   +1 more source

Extracellular Vesicle‐Transferred ATP‐Citrate Lyase Induces Monocyte Differentiation Toward Tumor‐Associated Macrophages and Fuels Hepatocellular Carcinoma Progression

Advanced Science, EarlyView.
Hepatocellular carcinoma (HCC)‐derived extracellular vesicles (EVs) enrich the metabolic enzyme ATP‐citrate lyase (ACLY). EV‐transferred ACLY enhances palmitate biosynthesis, increases the S‐palmitoylation and stability of multiple immune checkpoint proteins, augments the cellular immunosuppressive activity, and ultimately accelerates the malignant ...
Zhijun Liu, Haihong Lai, Qing Yang, Chaoyue Zhang, Bin Jia, Qiyi Chen, Yuling Deng, Fen Cao, Yuyu You, Zhe Li, Dongming Kuang, Bo Li   +11 more
wiley   +1 more source

Bcr/Abl Interferes with the Fanconi Anemia/BRCA Pathway: Implications in the Chromosomal Instability of Chronic Myeloid Leukemia Cells [PDF]

, 2010
Chronic myeloid leukemia (CML) is a malignant clonal disorder of the hematopoietic system caused by the expression of the BCR/ABL fusion oncogene. Although it is well known that CML cells are genetically unstable, the mechanisms accounting for this ...
Valeri, Antonio, Beatriz Albella, Agirre, Xabier, Casado, José A., Pujol, MR, Rio, P, Bueren, Juan, Ariana Jacome, Albella Beatriz, Maria Eugenia Alonso-Ferrero, Juan A Bueren, Alonso-Ferrero, Maria Eugenia, Calasanz, M.J, María Roser Pujol, Hanenberg, H. (H.), Jacome Ariana, Alonso-Ferrero, ME, Hanenberg, H, Perez, L, Pérez-Fuentes, L. (Laura), Agirre, X, Jacome, A, Juan A. Bueren, Jacome, Ariana, Río Paula, Pujol María Roser, Surrallés Jordi, Prosper-Cardoso, F. (Felipe), Pérez Laura, Maria José Calasanz, Pujol i Calvet, M. Roser, Surralles, J. (Jordi), Hanenberg, Helmut, Prosper Felipe, Helmut Hanenberg, Pérez, Laura, Casado, J. (J.A.), Jacome, A. (Ariana), Albella, Beatriz, Bueren, JA, Hanenberg Helmut, Agirre Xabier, Bueren, J.A. (Juan A.), Valeri, A. (Antonio), Rio, P. (Paula), Calasanz-Abinzano, M.J. (Maria Jose), Prosper, F, José A Casado, Laura Pérez, Paula Río, Surrallés i Calonge, Jordi, Río, Paula, Antonio Valeri, Casado José A., Valeri Antonio, Jordi Surrallés, Casado, JA, Calasanz Maria José, Felipe Prosper, Surralles, J, José A. Casado, Calasanz, MJ, Albella, B, Albella, B. (B.), Alonso-Ferrero Maria Eugenia, Valeri, A, Alonso-Ferrero, M. (M.E.), Pujol, M.R. (María Roser), Bueren Juan A., Aguirre-Ena, X. (Xabier), Xabier Agirre, Prosper, Felipe   +71 more
core   +1 more source

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade

Advanced Science, EarlyView.
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou, Yifei Zhu, Cheng Zeng, Jinlu Han, Huiying Huang, Doudou Li, Mingxi Lin, Yizi Jin, Qin Guo, Yuxin Yan, Xinhui Mao, Yifei Zhou, Jian Zhang   +12 more
wiley   +1 more source

Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance

Nature Communications
Drug resistance remains a challenge for targeted therapy of cancers driven by EML4-ALK and related fusion oncogenes. EML4-ALK forms cytoplasmic protein condensates, which result from networks of interactions between oncogene and adapter protein multimers.
David Gonzalez-Martinez, Lee Roth, Thomas R. Mumford, Juan Guan, Anh Le, Robert C. Doebele, Bo Huang, Asmin Tulpule, Magdalena Niewiadomska-Bugaj, Trever G. Bivona, Lukasz J. Bugaj   +10 more
doaj   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source